Galantamine transdermal patch - TAHO Pharmaceuticals
Alternative Names: TAH-8801Latest Information Update: 28 Sep 2024
At a glance
- Originator TAHO Pharmaceuticals
- Class Alkaloids; Antidementias; Benzazepines; Nootropics; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in China (Transdermal, Patch)
- 19 Sep 2022 Phase I development is still ongoing for Alzheimer's disease in China (TAHO Pharmaceuticals pipeline, September 2022)
- 19 Sep 2022 TAHO Pharmaceuticals plans a phase III trials in Alzheimer's-disease (TAHO Pharmaceuticals pipeline, September 2022)